董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl Firth | 男 | Chief Executive Officer and Director | 47 | 未披露 | 未持股 | 2020-08-03 |
| Lim Chin Hwee Damien | 男 | Director | 57 | 未披露 | 未持股 | 2020-08-03 |
| Andrew Howden | 男 | Chairman | 60 | 3.00万美元 | 未持股 | 2020-08-03 |
| Kelvin Sun | 男 | Director | 57 | 3.00万美元 | 未持股 | 2020-08-03 |
| Robert E. Hoffman | 男 | Director | 54 | 1.25万美元 | 未持股 | 2020-08-03 |
| Jun Wu | 男 | Director | 53 | 未披露 | 未持股 | 2020-08-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl Firth | 男 | Chief Executive Officer and Director | 47 | 未披露 | 未持股 | 2020-08-03 |
| Ben Goodger | 男 | General Counsel | 57 | 未披露 | 未持股 | 2020-08-03 |
| Kiran Asarpota | 男 | Vice President Finance | 41 | 未披露 | 未持股 | 2020-08-03 |
| Stephen Doyle | 男 | Chief Business Officer | 47 | 未披露 | 未持股 | 2020-08-03 |
| Kenneth Kobayashi | 男 | Chief Medical Officer | -- | 未披露 | 未持股 | 2020-08-03 |
董事简历
中英对照 | 中文 | 英文- Carl Firth
-
Carl Firth于2010年创立了我们的公司，并于2014年6月至2019年7月担任董事会主席，自2011年1月起担任首席执行官，自2010年7月起担任董事。在创立我们公司之前，Firth博士从2008年1月到2010年6月担任美银美林亚洲梦百合主管，支持梦百合公司的公共和私人融资，并为并购交易提供咨询。在加入银行业之前，Firth博士曾于1998年10月至2007年12月在阿斯利康（AstraZeneca）担任多个商业和研发职位，包括亚太地区业务发展总监和中国新产品开发总监。Firth博士目前是新加坡健康和生物医学科学国际咨询委员会的成员，自2017年9月起担任该职位，并担任新加坡剥削技术公司（Singapore&8217；s Exploit Technologies）的独立董事，该公司是A*STAR的商业化部门，该公司支持A*STAR努力通过推动创新和将其研究成果商业化来转变经济，他自2014年4月以来一直担任该职位。此前，Firth博士曾担任香港上市的Uni-Bio Sciences（中国领先的生物制药公司，从事针对中国梦百合市场的生物制药的研究，开发，生产和商业化）的独立董事，并于2014年4月至2017年11月担任该职位。他是Duke-Nus Medical School的兼职教授（2014年6月以来）。他持有Cambridge University Trinity College的分子生物学博士学位、London Business School的执行工商管理硕士学位，以及Cambridge University的分子生物学学士学位。
Carl Firth founded our company in 2010 and served as our Chairman of the board of directors from June 2014 to July 2019 as our Chief Executive Officer since January 2011 and as a director since July 2010. Prior to founding our company, Dr. Firth was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions, from January 2008 to June 2010. Prior to joining the banking industry, Dr. Firth worked for AstraZeneca from October 1998 to December 2007 in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Dr. Firth is currently a member of Singapore’s Health and Biomedical Sciences International Advisory Council, where he has served in such capacity since September 2017 and an independent director at Singapore’s Exploit Technologies, a commercialization arm of A*STAR, which supports A*STAR in its efforts to transform the economy by driving innovation and commercializing its research outcomes, where he has served in such capacity since April 2014. Previously, Dr. Firth was an independent director of Hong Kong listed Uni-Bio Sciences, a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialization of biopharmaceuticals for the Chinese healthcare market, where he served in such capacity from April 2014 to November 2017. Dr. Firth is an Adjunct Professor at Duke-NUS Medical School, a position he has held since June 2014. He holds a Ph.D. in Molecular Biology from Cambridge University Trinity College, an Executive M.B.A. from London Business School, and a B.A. in Molecular Biology from Cambridge University. - Carl Firth于2010年创立了我们的公司，并于2014年6月至2019年7月担任董事会主席，自2011年1月起担任首席执行官，自2010年7月起担任董事。在创立我们公司之前，Firth博士从2008年1月到2010年6月担任美银美林亚洲梦百合主管，支持梦百合公司的公共和私人融资，并为并购交易提供咨询。在加入银行业之前，Firth博士曾于1998年10月至2007年12月在阿斯利康（AstraZeneca）担任多个商业和研发职位，包括亚太地区业务发展总监和中国新产品开发总监。Firth博士目前是新加坡健康和生物医学科学国际咨询委员会的成员，自2017年9月起担任该职位，并担任新加坡剥削技术公司（Singapore&8217；s Exploit Technologies）的独立董事，该公司是A*STAR的商业化部门，该公司支持A*STAR努力通过推动创新和将其研究成果商业化来转变经济，他自2014年4月以来一直担任该职位。此前，Firth博士曾担任香港上市的Uni-Bio Sciences（中国领先的生物制药公司，从事针对中国梦百合市场的生物制药的研究，开发，生产和商业化）的独立董事，并于2014年4月至2017年11月担任该职位。他是Duke-Nus Medical School的兼职教授（2014年6月以来）。他持有Cambridge University Trinity College的分子生物学博士学位、London Business School的执行工商管理硕士学位，以及Cambridge University的分子生物学学士学位。
- Carl Firth founded our company in 2010 and served as our Chairman of the board of directors from June 2014 to July 2019 as our Chief Executive Officer since January 2011 and as a director since July 2010. Prior to founding our company, Dr. Firth was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions, from January 2008 to June 2010. Prior to joining the banking industry, Dr. Firth worked for AstraZeneca from October 1998 to December 2007 in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Dr. Firth is currently a member of Singapore’s Health and Biomedical Sciences International Advisory Council, where he has served in such capacity since September 2017 and an independent director at Singapore’s Exploit Technologies, a commercialization arm of A*STAR, which supports A*STAR in its efforts to transform the economy by driving innovation and commercializing its research outcomes, where he has served in such capacity since April 2014. Previously, Dr. Firth was an independent director of Hong Kong listed Uni-Bio Sciences, a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialization of biopharmaceuticals for the Chinese healthcare market, where he served in such capacity from April 2014 to November 2017. Dr. Firth is an Adjunct Professor at Duke-NUS Medical School, a position he has held since June 2014. He holds a Ph.D. in Molecular Biology from Cambridge University Trinity College, an Executive M.B.A. from London Business School, and a B.A. in Molecular Biology from Cambridge University.
- Lim Chin Hwee Damien
-
Lim Chin Hwee Damien自2016年4月起担任BV梦百合II Pte Ltd.的董事会成员和代表。他是Bioveda Capital公司（生命科学风险投资基金）的创始人，目前担任其普通合伙人（2000年以来）。他目前担任多个行业公司的非执行董事。他此前曾担任PrimePartners公司、Vickers Ballas Asset Management公司（均为私募股权资产管理公司）、Morgan Grenfell Asia公司（现由Deutsche Bank拥有的商业银行）的高级职务。他在休斯顿大学（University of Houston）获得学士学位。
Lim Chin Hwee Damien has served as a member of our board of directors and representative for BV Healthcare II Pte Ltd. since April 2016. He is the founder and currently serves as the General Partner of BioVeda Capital, a life science venture capital fund, a position he has held since 2000. He currently serves as a non-executive director of companies in a variety of industries. He has previously held senior positions in PrimePartners and Vickers Ballas Asset Management, both private equity asset management companies, and Morgan Grenfell Asia, a merchant bank now owned by Deutsche Bank. He received his B.B.A. from the University of Houston. - Lim Chin Hwee Damien自2016年4月起担任BV梦百合II Pte Ltd.的董事会成员和代表。他是Bioveda Capital公司（生命科学风险投资基金）的创始人，目前担任其普通合伙人（2000年以来）。他目前担任多个行业公司的非执行董事。他此前曾担任PrimePartners公司、Vickers Ballas Asset Management公司（均为私募股权资产管理公司）、Morgan Grenfell Asia公司（现由Deutsche Bank拥有的商业银行）的高级职务。他在休斯顿大学（University of Houston）获得学士学位。
- Lim Chin Hwee Damien has served as a member of our board of directors and representative for BV Healthcare II Pte Ltd. since April 2016. He is the founder and currently serves as the General Partner of BioVeda Capital, a life science venture capital fund, a position he has held since 2000. He currently serves as a non-executive director of companies in a variety of industries. He has previously held senior positions in PrimePartners and Vickers Ballas Asset Management, both private equity asset management companies, and Morgan Grenfell Asia, a merchant bank now owned by Deutsche Bank. He received his B.B.A. from the University of Houston.
- Andrew Howden
-
Andrew Howden自2019年7月起担任董事会主席，自2016年4月起担任董事会成员。他目前担任First Pharma P/L（澳大利亚制药公司）的执行主席（2016年9月以来）。他此前曾于2016年至2019年担任澳大利亚公司True Origins Company P/L的董事长，该公司参与了婴幼儿配方奶粉在中国和亚洲的营销。从2008年8月到2015年2月，他曾担任Inova Pharmaceuticals公司（亚太地区制药公司，开发和商业化跨越一系列治疗领域的药物）的首席执行官。此前，他曾于2007年至2008年担任阿斯利康亚太区总裁，这是一家为梦百合行业提供信息、服务和技术的公司，阿斯利康是一家跨国制药和生物制药公司，2007年至2008年担任阿斯利康亚太区Vice President，从2002年到2006年，他曾担任Quintiles Transnational公司（临床研究公司）的高级执行职务（从1998年到2002年）。Howden先生以前也曾在制药和梦百合行业的20多家公司的董事会任职。他获得了理学学士学位。来自新英格兰大学澳大利亚分校，和一个M.com。来自澳大利亚新南威尔士大学。
Andrew Howden has served as our Chairman of the board of directors since July 2019 and a member of our board of directors since April 2016. He currently serves as Executive Chairman of First Pharma P/L, an Australian pharmaceutical company, a position he has held since September 2016. He was previously Chairman of the True Origins Company P/L, an Australian company involved in the marketing of infant formula in China and Asia from 2016 to 2019. He previously served as the Chief Executive Officer of iNova Pharmaceuticals, an Asia Pacific pharmaceutical company developing and commercializing drugs across a range of therapeutic areas, from August 2008 to February 2015. Previously, he was the President of IMS Health, Asia Pacific, a provider of information, services and technology for the healthcare industry, from 2007 to 2008 Regional Vice President of Asia Pacific for AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, from 2002 to 2006 and he has held senior executive roles at Quintiles Transnational Inc., a clinical research company, from 1998 to 2002. Mr. Howden has also previously served on the board of directors of over 20 companies within the pharmaceutical and healthcare industries. He received a B.Sc. from the University of New England Australia, and an M.Com. from the University of New South Wales, Australia. - Andrew Howden自2019年7月起担任董事会主席，自2016年4月起担任董事会成员。他目前担任First Pharma P/L（澳大利亚制药公司）的执行主席（2016年9月以来）。他此前曾于2016年至2019年担任澳大利亚公司True Origins Company P/L的董事长，该公司参与了婴幼儿配方奶粉在中国和亚洲的营销。从2008年8月到2015年2月，他曾担任Inova Pharmaceuticals公司（亚太地区制药公司，开发和商业化跨越一系列治疗领域的药物）的首席执行官。此前，他曾于2007年至2008年担任阿斯利康亚太区总裁，这是一家为梦百合行业提供信息、服务和技术的公司，阿斯利康是一家跨国制药和生物制药公司，2007年至2008年担任阿斯利康亚太区Vice President，从2002年到2006年，他曾担任Quintiles Transnational公司（临床研究公司）的高级执行职务（从1998年到2002年）。Howden先生以前也曾在制药和梦百合行业的20多家公司的董事会任职。他获得了理学学士学位。来自新英格兰大学澳大利亚分校，和一个M.com。来自澳大利亚新南威尔士大学。
- Andrew Howden has served as our Chairman of the board of directors since July 2019 and a member of our board of directors since April 2016. He currently serves as Executive Chairman of First Pharma P/L, an Australian pharmaceutical company, a position he has held since September 2016. He was previously Chairman of the True Origins Company P/L, an Australian company involved in the marketing of infant formula in China and Asia from 2016 to 2019. He previously served as the Chief Executive Officer of iNova Pharmaceuticals, an Asia Pacific pharmaceutical company developing and commercializing drugs across a range of therapeutic areas, from August 2008 to February 2015. Previously, he was the President of IMS Health, Asia Pacific, a provider of information, services and technology for the healthcare industry, from 2007 to 2008 Regional Vice President of Asia Pacific for AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, from 2002 to 2006 and he has held senior executive roles at Quintiles Transnational Inc., a clinical research company, from 1998 to 2002. Mr. Howden has also previously served on the board of directors of over 20 companies within the pharmaceutical and healthcare industries. He received a B.Sc. from the University of New England Australia, and an M.Com. from the University of New South Wales, Australia.
- Kelvin Sun
-
Kelvin Sun自2016年4月以来一直担任我们的董事会成员。孙先生自1998年以来一直担任SAGA-Unitek Ventures的创始人兼总裁，该公司是一家风险投资和私募股权基金管理公司，专门投资于中间市场，成长型公司及其管理下的基金。他目前担任Wonderful Hi-Tech Co.Ltd.（台湾公共电线电缆制造公司）的独立董事（2010年6月以来），以及Tah Tong Textile Co.，Ltd.（台湾纺织制造公司）的独立董事。自2015年6月起担任该职位。孙先生目前还担任Pixon Technologies的董事会成员，该公司是一家台湾光学光源制造公司，他自2011年6月以来一直担任该职位NewMax Technology Co.，Ltd.，一家台湾光学镜头制造公司，他自2017年12月起担任该职位，并自2008年起担任台湾风险投资协会。他此前曾担任Chengxin VC Group（台湾风险投资公司）的高级官员（从1997年到1998年），也曾担任Emerson Electric公司（美国上市工业公司）的亚洲工程中心的董事，1995年至1997年，1992年至1993年，担任台湾光纤制造公司Prime Optical Fiber Corporation的研发部门负责人。他持有密歇根大学安娜堡分校（the University of Michigan at Ann Arbor）的工商管理硕士学位，以及Wayne State University的材料科学硕士学位。
Kelvin Sun has served as a member of our board of directors since April 2016. Mr. Sun has served as founder and president of Saga-Unitek Ventures, a venture capital and private equity fund management company, specializing in investing in middle-market, growth-oriented companies, as well as those funds under its management, since 1998. He currently serves as an independent director of Wonderful Hi-Tech Co. Ltd., a public Taiwanese electrical wire and cable manufacturing company, a position he has held since June 2010 and as an independent director of Tah Tong Textile Co., Ltd., a Taiwanese textile manufacturing company, a position he has held since June 2015. Mr. Sun also currently serves as a board member of Pixon Technologies, a Taiwanese optical light sources manufacturing company, a position he has held since June 2011 Newmax Technology Co., Ltd., a Taiwanese optical lens manufacturing company, a position he has held since December 2017 and the Taiwan Venture Capital Association, a position he has held since 2008. He previously served as the senior officer at Chengxin VC Group, a Taiwanese venture capital firm, from 1997 to 1998 as the Director for the Asian Engineering Center of Emerson Electric, a U.S. publicly listed industrial company, from 1995 to 1997 and as the R&D Section Leader at Prime Optical Fiber Corporation, a Taiwanese fiber optics manufacturing company, from 1992 to 1993. He holds an M.B.A. from the University of Michigan at Ann Arbor and an M.S. in Materials Science from Wayne State University. - Kelvin Sun自2016年4月以来一直担任我们的董事会成员。孙先生自1998年以来一直担任SAGA-Unitek Ventures的创始人兼总裁，该公司是一家风险投资和私募股权基金管理公司，专门投资于中间市场，成长型公司及其管理下的基金。他目前担任Wonderful Hi-Tech Co.Ltd.（台湾公共电线电缆制造公司）的独立董事（2010年6月以来），以及Tah Tong Textile Co.，Ltd.（台湾纺织制造公司）的独立董事。自2015年6月起担任该职位。孙先生目前还担任Pixon Technologies的董事会成员，该公司是一家台湾光学光源制造公司，他自2011年6月以来一直担任该职位NewMax Technology Co.，Ltd.，一家台湾光学镜头制造公司，他自2017年12月起担任该职位，并自2008年起担任台湾风险投资协会。他此前曾担任Chengxin VC Group（台湾风险投资公司）的高级官员（从1997年到1998年），也曾担任Emerson Electric公司（美国上市工业公司）的亚洲工程中心的董事，1995年至1997年，1992年至1993年，担任台湾光纤制造公司Prime Optical Fiber Corporation的研发部门负责人。他持有密歇根大学安娜堡分校（the University of Michigan at Ann Arbor）的工商管理硕士学位，以及Wayne State University的材料科学硕士学位。
- Kelvin Sun has served as a member of our board of directors since April 2016. Mr. Sun has served as founder and president of Saga-Unitek Ventures, a venture capital and private equity fund management company, specializing in investing in middle-market, growth-oriented companies, as well as those funds under its management, since 1998. He currently serves as an independent director of Wonderful Hi-Tech Co. Ltd., a public Taiwanese electrical wire and cable manufacturing company, a position he has held since June 2010 and as an independent director of Tah Tong Textile Co., Ltd., a Taiwanese textile manufacturing company, a position he has held since June 2015. Mr. Sun also currently serves as a board member of Pixon Technologies, a Taiwanese optical light sources manufacturing company, a position he has held since June 2011 Newmax Technology Co., Ltd., a Taiwanese optical lens manufacturing company, a position he has held since December 2017 and the Taiwan Venture Capital Association, a position he has held since 2008. He previously served as the senior officer at Chengxin VC Group, a Taiwanese venture capital firm, from 1997 to 1998 as the Director for the Asian Engineering Center of Emerson Electric, a U.S. publicly listed industrial company, from 1995 to 1997 and as the R&D Section Leader at Prime Optical Fiber Corporation, a Taiwanese fiber optics manufacturing company, from 1992 to 1993. He holds an M.B.A. from the University of Michigan at Ann Arbor and an M.S. in Materials Science from Wayne State University.
- Robert E. Hoffman
-
Robert E. Hoffman，2018年起担任公司董事长。2012年6月起，他在Arena担任高级副主席（负责财务）和首席财政官职务；2011年8月至2012年6月和2005年12月至2011年3月两段时期，他在Arena担任副主席（负责财务）和首席财政官职务；2004年6月至2005年10月，他担任副主席（负责财务）和首席会计师；2000年4月至2004年6月，他担任副主席（负责财务）；1997 年8月至2000年4月，他担任财务总监。2011年3月至8月，他在Polaris Group（生物药物制药公司）担任首席财政官。他是CombiMatrix公司（分子诊断公司）的董事会成员。他还在Financial Accounting Standards Board、Small Business Advisory Committee、the steering committee of the Association of Bioscience Financial Officers工作。此外，他还是San Diego Chapter of Financial Executives International的成员、前董事和总裁。他获有圣文德大学工商管理学士学位，并被授权为不活跃在加利福尼亚州的注册会计师。
Robert E. Hoffman,has served as Kintara Therapeutics, Inc. director since April 2018, as Kintara Therapeutics, Inc. Chairman since June 2018, as Kintara Therapeutics, Inc. Chief Executive Officer and President since November 2021, and as Kintara Therapeutics, Inc. interim Chief Financial Officer since June 1, 2023. He has served as a member of board of directors of ASLAN Pharmaceuticals, Inc., a publicly-held, clinical-stage immunology focused biopharmaceutical company, since October 2018, and as a member of the board of directors of FibroGenesis, a clinical-stage regenerative medicine company, since April 2021. He has also served as a member of board of directors, on the Audit Committee, and on the Human Resources and Compensation Committee of Antibe Therapeutics Inc. ("Antibe"), a publicly-held clinical-stage biotechnology company, since November 2020, and as Chairman of Antibe's board of directors since May 2022. Mr. Hoffman served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., a publicly-held pharmaceutical company, from April 2017 to October 2020. From July 2015 to September 2016, Mr. Hoffman served as Chief Financial Officer of AnaptysBio, Inc., a publicly-held biotechnology company. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena"), a biopharmaceutical company, prior to its acquisition by Pfizer Inc. in March 2022. From August 2011 to June 2012 and previously from December 2005 to March 2011, he served as Arena's Vice President, Finance and Chief Financial Officer and in a number of various roles of increasing responsibility from 1997 to December 2005. Mr. Hoffman formerly served as a member of the board of directors of Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and as a member of the board of directors of Kura Oncology, Inc., a cancer research company, from March 2015 to August 2021. He also previously served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc., a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University. - Robert E. Hoffman，2018年起担任公司董事长。2012年6月起，他在Arena担任高级副主席（负责财务）和首席财政官职务；2011年8月至2012年6月和2005年12月至2011年3月两段时期，他在Arena担任副主席（负责财务）和首席财政官职务；2004年6月至2005年10月，他担任副主席（负责财务）和首席会计师；2000年4月至2004年6月，他担任副主席（负责财务）；1997 年8月至2000年4月，他担任财务总监。2011年3月至8月，他在Polaris Group（生物药物制药公司）担任首席财政官。他是CombiMatrix公司（分子诊断公司）的董事会成员。他还在Financial Accounting Standards Board、Small Business Advisory Committee、the steering committee of the Association of Bioscience Financial Officers工作。此外，他还是San Diego Chapter of Financial Executives International的成员、前董事和总裁。他获有圣文德大学工商管理学士学位，并被授权为不活跃在加利福尼亚州的注册会计师。
- Robert E. Hoffman,has served as Kintara Therapeutics, Inc. director since April 2018, as Kintara Therapeutics, Inc. Chairman since June 2018, as Kintara Therapeutics, Inc. Chief Executive Officer and President since November 2021, and as Kintara Therapeutics, Inc. interim Chief Financial Officer since June 1, 2023. He has served as a member of board of directors of ASLAN Pharmaceuticals, Inc., a publicly-held, clinical-stage immunology focused biopharmaceutical company, since October 2018, and as a member of the board of directors of FibroGenesis, a clinical-stage regenerative medicine company, since April 2021. He has also served as a member of board of directors, on the Audit Committee, and on the Human Resources and Compensation Committee of Antibe Therapeutics Inc. ("Antibe"), a publicly-held clinical-stage biotechnology company, since November 2020, and as Chairman of Antibe's board of directors since May 2022. Mr. Hoffman served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., a publicly-held pharmaceutical company, from April 2017 to October 2020. From July 2015 to September 2016, Mr. Hoffman served as Chief Financial Officer of AnaptysBio, Inc., a publicly-held biotechnology company. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena"), a biopharmaceutical company, prior to its acquisition by Pfizer Inc. in March 2022. From August 2011 to June 2012 and previously from December 2005 to March 2011, he served as Arena's Vice President, Finance and Chief Financial Officer and in a number of various roles of increasing responsibility from 1997 to December 2005. Mr. Hoffman formerly served as a member of the board of directors of Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and as a member of the board of directors of Kura Oncology, Inc., a cancer research company, from March 2015 to August 2021. He also previously served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc., a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.
- Jun Wu
-
Jun Wu自2010年8月起担任公司的执行副总裁和财务总监。在加入公司之前，他担任iSoftStone Information Technology Group Co., Ltd.（位于中国（China）的信息技术外包公司，在纳斯达克证券交易所（NYSE）上市）担任财务总监（2008年3月-2010年8月）。2006年5月-2008年3月他担任HuaWei Technologies（一家通信解决方案提供商，位于中国（China））的副总裁，负责公司投资、财务部和税收，规划和报表和全球财务运营。1997年3月-2005年7月他在Lucent Technologies China（Lucent Technologies股份有限公司（Lucent Technologies Inc.）子公司）工作，领导财务、会计、合同管理和信息系统职能，他最后的职位是Lucent China的财务总监。在加入Lucent Technologies之前，他在 SAP （China） Co. Ltd.和 Walls （China) Co. Ltd.（Unilever的合资企业）担任不同的财务管理职位。他拥有位于华盛顿西雅图的城市大学（City University, Seattle, Washington）的工商管理硕士学位，是对外经济贸易大学（University of International Business and Economics）的会计毕业生。他是中国（PRC）公民。
Jun Wu has served as a member of our board of directors and representative for Alnair Investment since April 2016. Dr. Wu is currently the Chairman and Managing Partner at Cenova Ventures, a principal investment firm for healthcare venture funds, a position he has held since May 2009. Previously, Dr. Wu served as the Co-founder and Chief Executive Officer of Shanghai Genomics, a biotech company, from September 2001 to May 2005 and as an Executive Managing Director of GNI Limited, a Tokyo Exchange Listed biotech company, from June 2005 to April 2009. Dr. Wu has previously served as a director of over 20 companies and investment funds in the pharmaceutical industry. Dr. Wu holds a Ph.D. in Microbiology and Immunology from the University of California at San Francisco and a B.S. in Biology from San Jose State University. - Jun Wu自2010年8月起担任公司的执行副总裁和财务总监。在加入公司之前，他担任iSoftStone Information Technology Group Co., Ltd.（位于中国（China）的信息技术外包公司，在纳斯达克证券交易所（NYSE）上市）担任财务总监（2008年3月-2010年8月）。2006年5月-2008年3月他担任HuaWei Technologies（一家通信解决方案提供商，位于中国（China））的副总裁，负责公司投资、财务部和税收，规划和报表和全球财务运营。1997年3月-2005年7月他在Lucent Technologies China（Lucent Technologies股份有限公司（Lucent Technologies Inc.）子公司）工作，领导财务、会计、合同管理和信息系统职能，他最后的职位是Lucent China的财务总监。在加入Lucent Technologies之前，他在 SAP （China） Co. Ltd.和 Walls （China) Co. Ltd.（Unilever的合资企业）担任不同的财务管理职位。他拥有位于华盛顿西雅图的城市大学（City University, Seattle, Washington）的工商管理硕士学位，是对外经济贸易大学（University of International Business and Economics）的会计毕业生。他是中国（PRC）公民。
- Jun Wu has served as a member of our board of directors and representative for Alnair Investment since April 2016. Dr. Wu is currently the Chairman and Managing Partner at Cenova Ventures, a principal investment firm for healthcare venture funds, a position he has held since May 2009. Previously, Dr. Wu served as the Co-founder and Chief Executive Officer of Shanghai Genomics, a biotech company, from September 2001 to May 2005 and as an Executive Managing Director of GNI Limited, a Tokyo Exchange Listed biotech company, from June 2005 to April 2009. Dr. Wu has previously served as a director of over 20 companies and investment funds in the pharmaceutical industry. Dr. Wu holds a Ph.D. in Microbiology and Immunology from the University of California at San Francisco and a B.S. in Biology from San Jose State University.
高管简历
中英对照 | 中文 | 英文- Carl Firth
Carl Firth于2010年创立了我们的公司，并于2014年6月至2019年7月担任董事会主席，自2011年1月起担任首席执行官，自2010年7月起担任董事。在创立我们公司之前，Firth博士从2008年1月到2010年6月担任美银美林亚洲梦百合主管，支持梦百合公司的公共和私人融资，并为并购交易提供咨询。在加入银行业之前，Firth博士曾于1998年10月至2007年12月在阿斯利康（AstraZeneca）担任多个商业和研发职位，包括亚太地区业务发展总监和中国新产品开发总监。Firth博士目前是新加坡健康和生物医学科学国际咨询委员会的成员，自2017年9月起担任该职位，并担任新加坡剥削技术公司（Singapore&8217；s Exploit Technologies）的独立董事，该公司是A*STAR的商业化部门，该公司支持A*STAR努力通过推动创新和将其研究成果商业化来转变经济，他自2014年4月以来一直担任该职位。此前，Firth博士曾担任香港上市的Uni-Bio Sciences（中国领先的生物制药公司，从事针对中国梦百合市场的生物制药的研究，开发，生产和商业化）的独立董事，并于2014年4月至2017年11月担任该职位。他是Duke-Nus Medical School的兼职教授（2014年6月以来）。他持有Cambridge University Trinity College的分子生物学博士学位、London Business School的执行工商管理硕士学位，以及Cambridge University的分子生物学学士学位。
Carl Firth founded our company in 2010 and served as our Chairman of the board of directors from June 2014 to July 2019 as our Chief Executive Officer since January 2011 and as a director since July 2010. Prior to founding our company, Dr. Firth was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions, from January 2008 to June 2010. Prior to joining the banking industry, Dr. Firth worked for AstraZeneca from October 1998 to December 2007 in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Dr. Firth is currently a member of Singapore’s Health and Biomedical Sciences International Advisory Council, where he has served in such capacity since September 2017 and an independent director at Singapore’s Exploit Technologies, a commercialization arm of A*STAR, which supports A*STAR in its efforts to transform the economy by driving innovation and commercializing its research outcomes, where he has served in such capacity since April 2014. Previously, Dr. Firth was an independent director of Hong Kong listed Uni-Bio Sciences, a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialization of biopharmaceuticals for the Chinese healthcare market, where he served in such capacity from April 2014 to November 2017. Dr. Firth is an Adjunct Professor at Duke-NUS Medical School, a position he has held since June 2014. He holds a Ph.D. in Molecular Biology from Cambridge University Trinity College, an Executive M.B.A. from London Business School, and a B.A. in Molecular Biology from Cambridge University.- Carl Firth于2010年创立了我们的公司，并于2014年6月至2019年7月担任董事会主席，自2011年1月起担任首席执行官，自2010年7月起担任董事。在创立我们公司之前，Firth博士从2008年1月到2010年6月担任美银美林亚洲梦百合主管，支持梦百合公司的公共和私人融资，并为并购交易提供咨询。在加入银行业之前，Firth博士曾于1998年10月至2007年12月在阿斯利康（AstraZeneca）担任多个商业和研发职位，包括亚太地区业务发展总监和中国新产品开发总监。Firth博士目前是新加坡健康和生物医学科学国际咨询委员会的成员，自2017年9月起担任该职位，并担任新加坡剥削技术公司（Singapore&8217；s Exploit Technologies）的独立董事，该公司是A*STAR的商业化部门，该公司支持A*STAR努力通过推动创新和将其研究成果商业化来转变经济，他自2014年4月以来一直担任该职位。此前，Firth博士曾担任香港上市的Uni-Bio Sciences（中国领先的生物制药公司，从事针对中国梦百合市场的生物制药的研究，开发，生产和商业化）的独立董事，并于2014年4月至2017年11月担任该职位。他是Duke-Nus Medical School的兼职教授（2014年6月以来）。他持有Cambridge University Trinity College的分子生物学博士学位、London Business School的执行工商管理硕士学位，以及Cambridge University的分子生物学学士学位。
- Carl Firth founded our company in 2010 and served as our Chairman of the board of directors from June 2014 to July 2019 as our Chief Executive Officer since January 2011 and as a director since July 2010. Prior to founding our company, Dr. Firth was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions, from January 2008 to June 2010. Prior to joining the banking industry, Dr. Firth worked for AstraZeneca from October 1998 to December 2007 in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Dr. Firth is currently a member of Singapore’s Health and Biomedical Sciences International Advisory Council, where he has served in such capacity since September 2017 and an independent director at Singapore’s Exploit Technologies, a commercialization arm of A*STAR, which supports A*STAR in its efforts to transform the economy by driving innovation and commercializing its research outcomes, where he has served in such capacity since April 2014. Previously, Dr. Firth was an independent director of Hong Kong listed Uni-Bio Sciences, a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialization of biopharmaceuticals for the Chinese healthcare market, where he served in such capacity from April 2014 to November 2017. Dr. Firth is an Adjunct Professor at Duke-NUS Medical School, a position he has held since June 2014. He holds a Ph.D. in Molecular Biology from Cambridge University Trinity College, an Executive M.B.A. from London Business School, and a B.A. in Molecular Biology from Cambridge University.
- Ben Goodger
Ben Goodger自2016年11月起担任我们的总法律顾问。在加入我们之前，Goodger先生于2014年11月至2016年10月担任跨国律师事务所Osborne Clarke在英国的合伙人兼知识产权IP许可和交易主管。Goodger从2010年11月到2014年10月担任Edwards Wildman（一家跨国律师事务所）合伙人和IP商业化主管，以及Rouse&Co.执行主管和IP商业主管。1997年12月至2010年10月，在伦敦、牛津和上海担任跨国律师事务所International，1998年至1999年，担任非营利、非政治性伞式组织Licensing Executives Society的总裁。Goodger先生在牛津大学（Oxford University，Keble College）获得英语文学与语言硕士学位，他是英格兰与威尔士的律师，1986年10月注册。
Ben Goodger has served as our General Counsel since November 2016. Prior to joining us, Mr. Goodger was the Partner and Head of Intellectual Property IP Licensing and Transactions with Osborne Clarke in the United Kingdom, a multinational law firm, from November 2014 to October 2016. Mr. Goodger also previously served as Partner, Head of IP Commercialization, at Edwards Wildman in the United Kingdom, a multinational law firm, from November 2010 to October 2014 as Executive, Head of IP Commercial, at Rouse & Co. International in London, Oxford, and Shanghai, a multinational law firm, from December 1997 to October 2010 and as the President of Licensing Executives Society, a not for profit, non-political, umbrella organization, from 1998 to 1999. Mr. Goodger received his M.A. in English Literature & Language from Oxford University (Exhibitioner, Keble College) and he is a Solicitor of England & Wales, enrolled October 1986.- Ben Goodger自2016年11月起担任我们的总法律顾问。在加入我们之前，Goodger先生于2014年11月至2016年10月担任跨国律师事务所Osborne Clarke在英国的合伙人兼知识产权IP许可和交易主管。Goodger从2010年11月到2014年10月担任Edwards Wildman（一家跨国律师事务所）合伙人和IP商业化主管，以及Rouse&Co.执行主管和IP商业主管。1997年12月至2010年10月，在伦敦、牛津和上海担任跨国律师事务所International，1998年至1999年，担任非营利、非政治性伞式组织Licensing Executives Society的总裁。Goodger先生在牛津大学（Oxford University，Keble College）获得英语文学与语言硕士学位，他是英格兰与威尔士的律师，1986年10月注册。
- Ben Goodger has served as our General Counsel since November 2016. Prior to joining us, Mr. Goodger was the Partner and Head of Intellectual Property IP Licensing and Transactions with Osborne Clarke in the United Kingdom, a multinational law firm, from November 2014 to October 2016. Mr. Goodger also previously served as Partner, Head of IP Commercialization, at Edwards Wildman in the United Kingdom, a multinational law firm, from November 2010 to October 2014 as Executive, Head of IP Commercial, at Rouse & Co. International in London, Oxford, and Shanghai, a multinational law firm, from December 1997 to October 2010 and as the President of Licensing Executives Society, a not for profit, non-political, umbrella organization, from 1998 to 1999. Mr. Goodger received his M.A. in English Literature & Language from Oxford University (Exhibitioner, Keble College) and he is a Solicitor of England & Wales, enrolled October 1986.
- Kiran Asarpota
Kiran Asarpota自2010年11月以来一直担任我们的Vice President财务。加入我们之前，他曾担任Global Brands Group Holding Limited（公共品牌服装公司）的集团财务董事（从2006年到2010年），在那里他曾负责集团的企业和商业财务职能。Asarpota先生在英国伦敦南岸大学（London South Bank University）获得工商管理硕士学位，在牛津布鲁克斯（Oxford Brookes）获得工商管理硕士学位。
Kiran Asarpota has served as our Vice President Finance since November 2010. Prior to joining us, Mr. Asarpota was Group Finance Director at Global Brands Group Holding Limited, a public branded apparel company, from 2006 to 2010 where he was responsible for the group’s corporate and commercial finance functions. Mr. Asarpota received his M.B.A. from London South Bank University in the United Kingdom, and a B.B.M. from Oxford Brookes.- Kiran Asarpota自2010年11月以来一直担任我们的Vice President财务。加入我们之前，他曾担任Global Brands Group Holding Limited（公共品牌服装公司）的集团财务董事（从2006年到2010年），在那里他曾负责集团的企业和商业财务职能。Asarpota先生在英国伦敦南岸大学（London South Bank University）获得工商管理硕士学位，在牛津布鲁克斯（Oxford Brookes）获得工商管理硕士学位。
- Kiran Asarpota has served as our Vice President Finance since November 2010. Prior to joining us, Mr. Asarpota was Group Finance Director at Global Brands Group Holding Limited, a public branded apparel company, from 2006 to 2010 where he was responsible for the group’s corporate and commercial finance functions. Mr. Asarpota received his M.B.A. from London South Bank University in the United Kingdom, and a B.B.M. from Oxford Brookes.
- Stephen Doyle
自2018年2月以来，Stephen Doyle一直担任我们的Vice President商业和中国区负责人，并于2019年1月被任命为首席商务官。在加入我们之前，道尔先生于2014年1月至2018年2月担任全球制药公司勃林格殷格翰有限公司（Boehringer Ingelheim GmbH）的Vice President兼中国专业护理主管。2010年10月至2013年10月，道尔先生还曾担任赛诺菲公司（Sanofi S.A.）在上海的肿瘤、血液和移植业务部的Vice President，赛诺菲公司是一家全球性制药公司，2010年10月至2013年10月，他曾担任赛诺菲-安万特公司（Sanofi-Aventis）在新加坡的亚太地区、俄罗斯和印度的肿瘤业务区域商业总监，从2007年到2010年，他曾担任Sanofi-Aventis公司（位于巴黎）的董事兼科学传播、全球营销和肿瘤专营权主管（从2005年到2007年）。Doyle先生拥有英国罗伯特戈登大学（Robert Gordon University）的药学学士学位和英国德比大学（University of Derby）的临床药学硕士学位。
Stephen Doyle has served as our Vice President Commercial and Head of China since February 2018 and was appointed Chief Business Officer in January 2019. Prior to joining us, Mr. Doyle was the Vice President and Head of Specialty Care for China at Boehringer Ingelheim GmbH, a global pharmaceutical company, from January 2014 to February 2018. Mr. Doyle also previously served as the Vice President of Oncology, Haematology and Transplantation Business Unit with Sanofi S.A. in Shanghai, a global pharmaceutical company, from October 2010 to October 2013 as Regional Commercial Director for Oncology for Asia Pacific, Russia and India with Sanofi-aventis in Singapore, from 2007 to 2010 and as Director and Head of Scientific Communications, Global Marketing, Oncology Franchise with Sanofi-aventis in Paris from 2005 to 2007. Mr. Doyle holds a B.S. in Pharmacy from The Robert Gordon University in the United Kingdom and an M.S. in Clinical Pharmacy from the University of Derby in the United Kingdom.- 自2018年2月以来，Stephen Doyle一直担任我们的Vice President商业和中国区负责人，并于2019年1月被任命为首席商务官。在加入我们之前，道尔先生于2014年1月至2018年2月担任全球制药公司勃林格殷格翰有限公司（Boehringer Ingelheim GmbH）的Vice President兼中国专业护理主管。2010年10月至2013年10月，道尔先生还曾担任赛诺菲公司（Sanofi S.A.）在上海的肿瘤、血液和移植业务部的Vice President，赛诺菲公司是一家全球性制药公司，2010年10月至2013年10月，他曾担任赛诺菲-安万特公司（Sanofi-Aventis）在新加坡的亚太地区、俄罗斯和印度的肿瘤业务区域商业总监，从2007年到2010年，他曾担任Sanofi-Aventis公司（位于巴黎）的董事兼科学传播、全球营销和肿瘤专营权主管（从2005年到2007年）。Doyle先生拥有英国罗伯特戈登大学（Robert Gordon University）的药学学士学位和英国德比大学（University of Derby）的临床药学硕士学位。
- Stephen Doyle has served as our Vice President Commercial and Head of China since February 2018 and was appointed Chief Business Officer in January 2019. Prior to joining us, Mr. Doyle was the Vice President and Head of Specialty Care for China at Boehringer Ingelheim GmbH, a global pharmaceutical company, from January 2014 to February 2018. Mr. Doyle also previously served as the Vice President of Oncology, Haematology and Transplantation Business Unit with Sanofi S.A. in Shanghai, a global pharmaceutical company, from October 2010 to October 2013 as Regional Commercial Director for Oncology for Asia Pacific, Russia and India with Sanofi-aventis in Singapore, from 2007 to 2010 and as Director and Head of Scientific Communications, Global Marketing, Oncology Franchise with Sanofi-aventis in Paris from 2005 to 2007. Mr. Doyle holds a B.S. in Pharmacy from The Robert Gordon University in the United Kingdom and an M.S. in Clinical Pharmacy from the University of Derby in the United Kingdom.
- Kenneth Kobayashi
Kenneth Kobayashi，拥有超过25年的药物开发、临床实践和监管事务经验，担任皮肤科专家。他最近担任Dermira公司（Eli Lilly公司的子公司）的高级医疗董事，在那里他负责开发Lebrikizumab公司（特应性皮炎的单克隆抗体），并支持五个3期注册研究以及两个新化合物的临床前和早期临床开发。加入Dermira公司之前，他曾担任Novartis公司的免疫学、肝病学和皮肤病学全球开发部门的临床开发医学董事，在那里他曾支持抗IL-17c和抗IgE单克隆抗体的开发计划。他也曾担任利欧股份Pharma公司的高级和全球领导职务，也曾担任渥太华大学和渥太华医院的副教授、皮肤科主任和主任。
Kenneth Kobayashi has more than 25 years of experience in drug development, clinical practice and regulatory affairs as a Dermatology expert. He most recently served as Senior Medical Director at Dermira, a subsidiary of Eli Lilly, where he was responsible for the development of lebrikizumab, a monoclonal antibody for atopic dermatitis, and supported five Phase 3 registration studies together with preclinical and early clinical development for two novel compounds. Prior to joining Dermira, Dr Kobayashi was Clinical Development Medical Director at Novartis, in the Immunology, Hepatology and Dermatology Global Development Unit, where he supported the development programs for anti-IL-17C and anti-IgE monoclonal antibodies. He has also held senior and global leadership positions at LEO Pharma and was an Associate Professor, and Chair and Chief of the Division of Dermatology at the University of Ottawa and The Ottawa Hospital.- Kenneth Kobayashi，拥有超过25年的药物开发、临床实践和监管事务经验，担任皮肤科专家。他最近担任Dermira公司（Eli Lilly公司的子公司）的高级医疗董事，在那里他负责开发Lebrikizumab公司（特应性皮炎的单克隆抗体），并支持五个3期注册研究以及两个新化合物的临床前和早期临床开发。加入Dermira公司之前，他曾担任Novartis公司的免疫学、肝病学和皮肤病学全球开发部门的临床开发医学董事，在那里他曾支持抗IL-17c和抗IgE单克隆抗体的开发计划。他也曾担任利欧股份Pharma公司的高级和全球领导职务，也曾担任渥太华大学和渥太华医院的副教授、皮肤科主任和主任。
- Kenneth Kobayashi has more than 25 years of experience in drug development, clinical practice and regulatory affairs as a Dermatology expert. He most recently served as Senior Medical Director at Dermira, a subsidiary of Eli Lilly, where he was responsible for the development of lebrikizumab, a monoclonal antibody for atopic dermatitis, and supported five Phase 3 registration studies together with preclinical and early clinical development for two novel compounds. Prior to joining Dermira, Dr Kobayashi was Clinical Development Medical Director at Novartis, in the Immunology, Hepatology and Dermatology Global Development Unit, where he supported the development programs for anti-IL-17C and anti-IgE monoclonal antibodies. He has also held senior and global leadership positions at LEO Pharma and was an Associate Professor, and Chair and Chief of the Division of Dermatology at the University of Ottawa and The Ottawa Hospital.